{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008450","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.339071+00:00","generated_at":"2026-06-01T13:11:22.717754+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Virios Therapeutics prices $1.7M public offering of 8.5M shares at $0.20/share for Long-COVID study prep","bullets":["Priced public offering of 8,500,000 shares at $0.20 per share for gross proceeds of approx. $1.7M.","Net proceeds to fund preparatory activities for planned IMC-2 Long-COVID Phase 2b study and general corporate purposes.","Offering expected to close on May 22, 2024; Maxim Group LLC acting as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008450","json":"https://secwatch.observer/filing/0001558370-24-008450.json","markdown":"https://secwatch.observer/filing/0001558370-24-008450.md","text":"https://secwatch.observer/filing/0001558370-24-008450.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024008450/0001558370-24-008450-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024008450/viri-20240519x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T13:11:22.717754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}